BBIO Stock Summary and Trading Ideas (Bridgebio Pharma | NASDAQ:BBIO)

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. Its key drug is Attruby (acoramidis), an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Bridgebio Pharma trades on the NASDAQ stock market under the symbol BBIO.

As of November 11, 2026, BBIO stock price declined to $78.44 with 20,544 million shares trading.

BBIO has a beta of 0.12, meaning it tends to be less sensitive to market movements. BBIO has a correlation of 0.00 to the broad based SPY ETF.

BBIO has a market cap of $15.28 billion. This is considered a Large Cap stock.

Last quarter Bridgebio Pharma reported $353 million in Revenue and -$.42 earnings per share. This beat revenue expectation by $57 million and exceeded earnings estimates by $.15.

In the last 3 years, BBIO traded as high as $93.42 and as low as $21.62.

The top ETF exchange traded funds that BBIO belongs to (by Net Assets): VTI, VB, XBI, VBK, VXF.

BBIO has outperformed the market in the last year with a price return of +24.9% while the SPY ETF gained +12.2%. However, in the short term, BBIO had mixed performance relative to the market. It has underperformed in the last 3 months, returning -7.4% vs -1.9% return in SPY. But in the last 2 weeks, BBIO shares have fared better than the market returning +13.1% compared to SPY -1.7%.

BBIO support price is $76.76 and resistance is $80.58 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BBIO shares will trade within this expected range on the day.